PET/CT在恶性胸膜间皮瘤疗效评估中的作用
本文综述恶性胸膜间皮瘤的疗效评估标准,包括mRECIST、iRECIST和PERCIST,并讨论PET/CT在该病管理中的潜在未来作用。近期研究提示,FDG-PET/CT在疗效评估方面可能优于基于CT的标准。
要点
- 恶性胸膜间皮瘤呈胸膜相关、常为多灶的套膜状生长,诊断存在挑战。
- 新型免疫治疗尚无影像学通用疗效标准,近期研究提示FDG-PET/CT评估可能优于CT标准。
- 本文概述mRECIST、iRECIST和PERCIST等间皮瘤疗效评估标准。
核心结论
- 近期研究提示,FDG-PET/CT在恶性胸膜间皮瘤疗效评估方面可能优于基于CT的标准。
- 本文旨在概述mRECIST、iRECIST和PERCIST等专用疗效评估标准,并讨论PET/CT未来在该病管理中的潜在作用。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 恶性胸膜间皮瘤为罕见癌症,但其发病率在上升,预计未来数年将继续上升。
- 该病呈套膜状、胸膜相关、常为多灶的生长,造成诊断挑战。
- 越来越多的间皮瘤正接受新型免疫治疗,而此类治疗尚无影像学通用疗效标准。
关键数值与推荐
- 文中汇总的疗效评估标准包括mRECIST、iRECIST和PERCIST,具体数值原文未报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant pleural mesothelioma is a rare type of cancer, whose incidence, however, is increasing and will presumably continue to rise in the coming years. Key features of this disease comprise its mantle-shaped, pleura-associated, often multifocal growth, which cause diagnostic challenges. A growing number of mesotheliomas are being treated with novel immunotherapies for which no image derived general response criteria have been established. However, recent studies indicate that FDG-PET/CT could be superior for response assessment compared to CT-based criteria. This article aims at providing an overview of response assessment criteria dedicated to malignant pleural mesothelioma, such as mRECIST, iRECIST, and PERCIST. In addition, the potential future role of PET/CT in the management of malignant pleural mesothelioma will also be discussed.
引用
- Sandach P, Seifert R, Fendler WP, et al. A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. Semin Nucl Med. 2022. PMID: 35624033. doi:10.1053/j.semnuclmed.2022.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。